This unique course touches upon the radiobiological, radiochemical and dosimetric aspects in the development of radiopharmaceuticals. The course is organized under the umbrella of the PRISMAP project (www.prismap.eu).
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101008571 (PRISMAP).
Specific topics that will be covered are:
- Radiobiological aspects of the use of radiopharmaceuticals: cancer cell inhibiting and cytotoxicity for normal cells;
- Radiochemistry in the development of radiopharmaceuticals;
- Dosimetric and microdosimetric aspects of the use of radiopharmaceuticals;
- Examples of specific research studies in the development of radiopharmaceuticals.
PhD students as well as post-docs, junior scientists or technicians interested in radiopharmaceuticals for medical applications. The course can allow a maximum number of 20 participants.